Published in Blood Weekly, July 7th, 2005
These data were presented during the European Renal Association - European Dialysis and Transplant Association congress in Istanbul, Turkey. Phase II results with CERA are being confirmed in an extensive phase III clinical program.
"These findings suggest that CERA may represent a convenient treatment alternative with less-frequent dosing,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.